Trial · NCT05875948
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
NCT05875948, Phase 2, Unknown, River 2 Renal Corp.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome. Trials, record NCT05875948. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05875948
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
- NCT number
- NCT05875948
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 95 participants, estimated
- Lead sponsor
- River 2 Renal Corp.
- Conditions
- Hepatorenal Syndrome, Acute Kidney Injury
- Interventions
- R2R01, Terlipressin
- First posted
- 2023-05-25
- Last updated
- 2023-10-03
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety Evaluation Criteria - Treatment Emergent Adverse Events (TEAEs) | From first dose of study drug to 30 days post last dose | Safety and tolerability will be assessed by occurrence of TEAEs. Outcome will be reported as the count of participant experiencing TEAEs. |
| Primary | Safety Evaluation Criteria - Change in Weight | Change from screening through Day 30 | Safety and tolerability will be assessed by change in body weight |
| Primary | Safety Evaluation Criteria - Vital Signs - Respiration Rate | Change from screening through Day 30 | Safety and tolerability will be assessed by change in respiration rate |
| Primary | Safety Evaluation Criteria - Vital Signs - Body Temperature | Change from screening through Day 30 | Safety and tolerability will be assessed by change in body temperature |
| Primary | Safety Evaluation Criteria - Vital Signs - Continuous pulse oximetry (SpO2) | Change from baseline through Day 30 | Safety and tolerability will be assessed by change in SpO2 |
| Primary | Safety Evaluation Criteria - Vital Signs - Systolic Blood Pressure (SBP) | Change from screening through Day 30 | Safety and tolerability will be assessed by change in SBP |
| Primary | Safety Evaluation Criteria - Vital Signs - Diastolic Blood pressure (DBP) | Change from screening through Day 30 | Safety and tolerability will be assessed by change in DBP |
| Primary | Safety Evaluation Criteria - Vital Signs - Heart Rate (HR) | Change from screening through Day 30 | Safety and tolerability will be assessed by change in Heart Rate (HR) |
| Primary | Safety Evaluation Criteria - ECGs - PR interval | Change from screening to Day 14 or hospital discharge | Safety and tolerability will be assessed by occurrence of ECGs |
| Primary | Safety Evaluation Criteria - ECGs - RR interval | Change from screening to Day 14 or hospital discharge | Safety and tolerability will be assessed by occurrence of ECGs |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05875948
GET https://conductscience.org/api/trials/v1/NCT05875948/registered